# Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

> **NCT02202395** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 120 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** LTS 0.25mg
- **DRUG:** LTS 0.5mg
- **DRUG:** LTS 1.0mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02202395
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-04-30
- **Final completion:** 2016-12-28
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202395, "Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02202395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*